BORA-dependent PLK1 regulation: A new weapon for cancer therapy?

The mitotic kinase polo like kinase 1 (PLK1) is overexpressed in many cancers and its inhibition slows down proliferation and increases apoptosis in cancer cell lines. Understanding how PLK1 is activated is therefore crucial for the development of novel PLK1 inhibitors with anticancer properties. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirillo, Luca, Thomas, Yann, Pintard, Lionel, Gotta, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068183/
https://www.ncbi.nlm.nih.gov/pubmed/27857970
http://dx.doi.org/10.1080/23723556.2016.1199265
Descripción
Sumario:The mitotic kinase polo like kinase 1 (PLK1) is overexpressed in many cancers and its inhibition slows down proliferation and increases apoptosis in cancer cell lines. Understanding how PLK1 is activated is therefore crucial for the development of novel PLK1 inhibitors with anticancer properties. We recently identified a conserved regulatory loop leading to PLK1 activation that involves cyclin-dependent kinase 1 (CDK1).

Ejemplares similares